Lack of consensus identifies important areas for future clinical research: Advanced Prostate Cancer Consensus Conference (APCCC) 2019 findings

Management of patients with advanced prostate cancer—metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022

“…Similar to the results of prior APCCC meetings, there was a high level of enthusiasm for MDT even though strong data to support this approach is lacking. We want to raise awareness that several randomised trials of MDT are now underway-eligible patients should be enroled in these trials, and clinicians should not assume that they know what is best for patients before these studies read out [94].…”

EAU-EANM Consensus Statements on the Role of Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography in Patients with Prostate Cancer and with Respect to [177Lu]Lu-PSMA Radioligand Therapy

“…In recognition of the growing importance of PSMAtargeting radiopharmaceuticals in the diagnosis and treatment of PCa, the EAU in collaboration with the EANM recruited a panel of international PCa experts from different specialties to assess the available evidence and provide their collective expert opinion regarding PSMA-based imaging and therapy, with the aim of developing interim guidance on PSMA PET/CT imaging in patients suitable for [ 177 Lu]Lu-PSMA therapy until better evidence emerges [8].…”

The Current Therapeutic Landscape for Metastatic Prostate Cancer

“…Often, this gap in the field can be attributed to barriers such as funding, dominant pharmaceutical manufacturers, and the lack of valuable partnerships within the science community. While this issue remains large in the United States, it also extends on the global level to a wide range of opinions on various clinical approaches in oncology [ 119 ]. Likewise, the process of selecting participants for a clinical trial lends itself to tailor-made cohorts that align with the treatment.…”